Welcome to the Pfizer Rare Diseases Consortium
Our mission is to develop new medicines for the treatment of rare diseases by bringing academic scientists (from GMEC and other institutions) , physicians and patient groups together with Pfizer’s world class drug development expertise, tools and resources.
We believe collaboration across the rare disease community is key to future drug development, and this belief sits at the heart of the RDC.
The RDC will accelerate the pace of innovation in delivering new rare disease medicines.
Our current call is for novel biologic strategies and molecules and AAV gene therapy programmes across the rare disease landscape.
We want to hear from scientists working in GMEC and RDC affiliated academic institutions who can apply through their university.
Click here if you would like to find out more about how your institution could become an RDC collaborator.